Connective Therapeutics, Soltec Research Pty Ltd. deal

CNCT received an exclusive North American license to develop and market betamethasone mousse, a foam mousse formulation of the cortiscosteroid dermatology drug betamethasone valerate. CNCT, which also has an exclusive option on Soltec's foam mousse system to deliver other compounds, will pay a licensing fee of less than $100,000 and royalties between 5-9 percent. ...